150 related articles for article (PubMed ID: 27275747)
1. Immunoregulatory Effects of Everolimus on In Vitro Alloimmune Responses.
Levitsky J; Miller J; Huang X; Gallon L; Leventhal JR; Mathew JM
PLoS One; 2016; 11(6):e0156535. PubMed ID: 27275747
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory effects of belatacept on allospecific regulatory T-cell generation in humans.
Levitsky J; Miller J; Huang X; Chandrasekaran D; Chen L; Mathew JM
Transplantation; 2013 Oct; 96(8):689-96. PubMed ID: 23883971
[TBL] [Abstract][Full Text] [Related]
3. Allospecific regulatory effects of sirolimus and tacrolimus in the human mixed lymphocyte reaction.
Levitsky J; Gallon L; Miller J; Tambur AR; Leventhal J; Flaa C; Huang X; Sarraj B; Wang E; Mathew JM
Transplantation; 2011 Jan; 91(2):199-206. PubMed ID: 21239962
[TBL] [Abstract][Full Text] [Related]
4. Sirolimus vs mycophenolate moftile in Tacrolimus based therapy following induction with Antithymocyte globulin promotes regulatory T cell expansion and inhibits RORγt and T-bet expression in kidney transplantation.
Jamali S; Sarafnejad A; Ahmadpoor P; Nafar M; Karimi M; Eteghadi A; Yekaninejad MS; Amirzargar AA
Hum Immunol; 2019 Sep; 80(9):739-747. PubMed ID: 30597187
[TBL] [Abstract][Full Text] [Related]
5. Role of FK778 alone or in combination with tacrolimus or mTOR inhibitors as an immunomodulator of immunofunctions: in vitro evaluation of T cell proliferation and the expression of lymphocyte surface antigens.
Millán O; Jiménez O; Fortuna V; Barceló JJ; Brunet M
Int J Immunopathol Pharmacol; 2006; 19(2):317-30. PubMed ID: 16831299
[TBL] [Abstract][Full Text] [Related]
6. Differential Effects of Calcineurin and Mammalian Target of Rapamycin Inhibitors on Alloreactive Th1, Th17, and Regulatory T Cells.
Gallon L; Traitanon O; Yu Y; Shi B; Leventhal JR; Miller J; Mas V; L X; Mathew JM
Transplantation; 2015 Sep; 99(9):1774-84. PubMed ID: 25905982
[TBL] [Abstract][Full Text] [Related]
7. Treatment with mTOR inhibitors after liver transplantation enables a sustained increase in regulatory T-cells while preserving their suppressive capacity.
Ghazal K; Stenard F; Dahlqvist G; Barjon C; Aoudjehane L; Scatton O; Conti F
Clin Res Hepatol Gastroenterol; 2018 Jun; 42(3):237-244. PubMed ID: 29175009
[TBL] [Abstract][Full Text] [Related]
8. Different immunosuppressive combinations on T-cell regulation in renal transplant recipients.
Fourtounas C; Dousdampanis P; Sakellaraki P; Rodi M; Georgakopoulos T; Vlachojannis JG; Mouzaki A
Am J Nephrol; 2010; 32(1):1-9. PubMed ID: 20484893
[TBL] [Abstract][Full Text] [Related]
9. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.
Favi E; Citterio F; Spagnoletti G; Gargiulo A; Delreno F; Romagnoli J; Castagneto M
Transplant Proc; 2009 May; 41(4):1152-5. PubMed ID: 19460503
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the impact of conventional immunosuppressant on the establishment of murine transplantation tolerance - an experimental study.
Katsumata H; Miyairi S; Ikemiyagi M; Hirai T; Fukuda H; Kanzawa T; Ishii R; Saiga K; Ishii Y; Omoto K; Okumi M; Yokoo T; Tanabe K
Transpl Int; 2019 Apr; 32(4):443-453. PubMed ID: 30561097
[TBL] [Abstract][Full Text] [Related]
11. Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients.
Tenderich G; Fuchs U; Zittermann A; Muckelbauer R; Berthold HK; Koerfer R
Clin Transplant; 2007; 21(4):536-43. PubMed ID: 17645716
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine.
Spagnoletti G; Citterio F; Favi E; Rossi E; Delreno F; De Santis I; Salerno MP; Gargiulo A; Castagneto M
Transplant Proc; 2009 May; 41(4):1175-7. PubMed ID: 19460509
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic Drug-Drug Interaction on Human Peripheral Blood Mononuclear Cells Between Everolimus and Tacrolimus at the Therapeutic Concentration Range in Renal Transplantation.
Okihara M; Takeuchi H; Akiyama S; Yoshinaga R; Osato S; Akashi I; Kihara Y; Konno O; Iwamoto H; Oda T; Tanaka S; Unezaki S; Hirano T
Ann Transplant; 2021 Feb; 26():e928817. PubMed ID: 33633104
[TBL] [Abstract][Full Text] [Related]
14. Favorable effects of alemtuzumab on allospecific regulatory T-cell generation.
Levitsky J; Leventhal JR; Miller J; Huang X; Chen L; Chandrasekaran D; Tambur AR; Mathew JM
Hum Immunol; 2012 Feb; 73(2):141-9. PubMed ID: 22154724
[TBL] [Abstract][Full Text] [Related]
15. CD45RA Distinguishes CD4+CD25+CD127-/low TSDR Demethylated Regulatory T Cell Subpopulations With Differential Stability and Susceptibility to Tacrolimus-Mediated Inhibition of Suppression.
Arroyo Hornero R; Betts GJ; Sawitzki B; Vogt K; Harden PN; Wood KJ
Transplantation; 2017 Feb; 101(2):302-309. PubMed ID: 28118317
[TBL] [Abstract][Full Text] [Related]
16. Clinically-relevant cyclosporin and rapamycin concentrations enhance regulatory T cell function to a similar extent but with different mechanisms: an in-vitro study in healthy humans.
Fanigliulo D; Lazzerini PE; Capecchi PL; Ulivieri C; Baldari CT; Laghi-Pasini F
Int Immunopharmacol; 2015 Feb; 24(2):276-284. PubMed ID: 25536542
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcome in heart transplant recipients receiving everolimus in combination with dosage reduction of the calcineurin inhibitor cyclosporine A or tacrolimus.
Fuchs U; Zittermann A; Ensminger SM; Schulz U; Gummert JF
Transpl Immunol; 2014 Aug; 31(2):87-91. PubMed ID: 24932812
[TBL] [Abstract][Full Text] [Related]
18. Differential Effects of Tacrolimus versus Sirolimus on the Proliferation, Activation and Differentiation of Human B Cells.
Traitanon O; Mathew JM; La Monica G; Xu L; Mas V; Gallon L
PLoS One; 2015; 10(6):e0129658. PubMed ID: 26087255
[TBL] [Abstract][Full Text] [Related]
19. Tacrolimus pharmacokinetic drug interactions: effect of prednisone, mycophenolic acid or sirolimus.
Park SI; Felipe CR; Pinheiro-Machado PG; Garcia R; Fernandes FB; Casarini DE; Tedesco-Silva H; Medina-Pestana JO
Fundam Clin Pharmacol; 2009 Feb; 23(1):137-45. PubMed ID: 19267777
[TBL] [Abstract][Full Text] [Related]
20. Relative impact of CD4+CD25+ regulatory T cells and tacrolimus on inhibition of T-cell proliferation in patients with atopic dermatitis.
Vukmanovic-Stejic M; McQuaid A; Birch KE; Reed JR; Macgregor C; Rustin MH; Akbar AN
Br J Dermatol; 2005 Oct; 153(4):750-7. PubMed ID: 16181456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
